In Vitro Diagnostics (Segment)
Tests performed on biological samples outside the body to inform diagnosis or treatment.
Definition
IVDs include immunoassays, molecular diagnostics (PCR, NGS), point-of-care tests, hematology, and clinical chemistry. The segment spans high-volume central-lab platforms to consumer at-home tests. Business models range from instrument sales to reagent rental, where recurring consumable revenue funds the installed base. In the US, IVDs are regulated by FDA and test use is governed by CLIA lab categories, while the EU regulates them under the IVDR. Payment is driven largely by the Clinical Laboratory Fee Schedule and private payer policies.What this means in practice
Regulatory shifts (EU IVDR, FDA's LDT rule) and the rise of multi-cancer early detection (MCED) and minimal-residual-disease (MRD) testing are reshaping investment and competitive dynamics.Examples
- A manufacturer developing a new molecular diagnostic test for a life-threatening disease must navigate Class D conformity assessment under the EU IVDR, requiring notified body involvement and extensive clinical evidence.
- An IVD company submitting a new immunoassay for allergy testing to the FDA would likely seek 510(k) clearance, demonstrating substantial equivalence to a legally marketed predicate device.
- A hospital laboratory offering an LDT for a rare genetic condition must monitor evolving FDA guidance to ensure its service remains compliant with federal regulations.
- •A common pitfall is misunderstanding the specific classification rules for an IVD, which can lead to incorrect conformity assessment pathways and delays.
- •Failing to keep up with evolving regulatory frameworks, such as the EU IVDR transition or new FDA guidance on Laboratory Developed Tests (LDTs), can result in non-compliance.
- •Assuming that a device cleared in one jurisdiction will automatically be accepted in another without fulfilling local regulatory requirements is a mistake.
- •Neglecting the cybersecurity risks associated with connected IVDs, especially those processing sensitive patient data, can lead to vulnerabilities and data breaches.
- •Underestimating the post-market surveillance requirements for IVDs across different regulatory environments can result in inadequate monitoring and reporting.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsIVD that identifies patients who will benefit from a specific drug.
IVD designed, manufactured, and used within a single CLIA laboratory.
Regulation (EU) 2017/746 governing in vitro diagnostic medical devices in the EU.
More in Market Segments
· Same categoryLasers, RF, ultrasound, cryolipolysis, and IPL systems used for medical and cosmetic indications, body contouring, hair removal, skin tightening, vascular lesions.
Software that analyzes medical images to triage, detect, or quantify disease.
Implantable and external devices that monitor and treat cardiac arrhythmias, pacemakers, ICDs, CRT devices, and insertable cardiac monitors.
Devices for diagnosing, monitoring, or treating cardiovascular disease.
Where this term appears across MedTech Terms.
Sources
4 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
- 1AdvaMedDxTier 4 VerifiedAdvaMedDxadvameddx.org
- 2MedTech Europe - Facts & FiguresTier 4 VerifiedMedTech Europemedtecheurope.org
- 3MedTech DiveTier 4 VerifiedMedTech Divemedtechdive.com
- 4In vitro diagnosticsTier 2 VerifiedU.S. Food and Drug Administration (FDA)fda.gov
Inline markers like [1] jump to the matching reference above.